As payers increasingly challenge the gap between trial data and real-world outcomes, defending premium oncology pricing requires more than clinical evidence — it demands transparency. This case study explores how a global pharmaceutical leader partnered with QUANTUM to deploy a Real-World Evidence framework that protected premium pricing, eliminated payer uncertainty, and accelerated first-line therapy status by six months.

How AI-Driven Sales Force Transformation Revived a Cardiovascular Device Company's Growth

The Challenge

A mid-cap cardiovascular device firm found their traditional sales model failing. Reps were struggling to get 5 minutes with cardiologists, and when they did, they were dismissed as "commodity vendors." High staff turnover and stagnant growth in the US market threatened their Series D funding valuation.

The Solution

The QUANTUM Solution: We executed a total Commercial Muscle Transformation.

• • The "Consultant" CRM: We replaced their legacy CRM with an AI-driven platform that alerted reps to local "Patient Flow" shifts and clinical publication updates, giving them a "reason to call" beyond a sales pitch.
  • Visconti Executive Coaching: We put the entire regional management team through a 12-week intensive on "Clinical Value Leadership." They moved from tracking "Call Volumes" to "Stakeholder Influence Scores."
  • Virtual Proctoring Hub: We deployed AR (Augmented Reality) headsets for field clinical specialists, allowing them to support surgeons remotely, doubling their geographic coverage overnight.

The Impact

• 35% Increase in "High-Value" Interactions:Physicians reported seeing the reps as clinical partners rather than vendors.

• 15% Reduction in SGA: Remote proctoring significantly lowered travel costs and allowed for territory consolidation without losing revenue.

• Talent Retention: Sales force churn dropped from 25% to 8% in the first year.